Skip to main content
Top
Published in: Diabetes Therapy 4/2017

Open Access 01-08-2017 | Brief Report

Hypoglycemic Event Frequency and the Effect of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections

Authors: Tonya Riddlesworth, David Price, Nathan Cohen, Roy W. Beck

Published in: Diabetes Therapy | Issue 4/2017

Login to get access

Abstract

Introduction

The benefits of continuous glucose monitoring (CGM) in type 1 diabetes have been established among adults using insulin pumps. The DIAMOND randomized clinical trial examined the effectiveness of using CGM in improving glycemic control in participants using insulin injections. The frequency of hypoglycemic events in this trial has not been previously examined.

Methods

Adults with type 1 diabetes using multiple daily insulin injections (MDI) with A1C values of 7.5% to 9.9% and not using CGM were randomized to adopt CGM (CGM group, n = 105) or continue with usual care (control group, n = 53). CGM data were collected from both groups at the beginning of the study and after 3 and 6 months. A hypoglycemic event was defined as a series of at least CGM values less than 3.0 mmol/L, separated by 20 min or more, with no intervening values of 3.0 mmol/L or more. Hypoglycemic event rates per 24 h were compared using a linear model adjusted for the baseline event rate per 24 h, baseline A1C, and site as a random effect.

Results

In the CGM group, the median hypoglycemic event rate fell by 30% (0.23 per 24 h at baseline and 0.16 per 24 h at follow-up) while in the control group the rate was nearly unchanged (0.31 per 24 h at baseline and 0.30 per 24 h at follow-up; p value = 0.03).

Conclusion

In the DIAMOND randomized controlled trial, participants in the CGM group experienced a greater reduction in hypoglycemic event rate than participants receiving usual care in the control group.

Trial Registration

Clinicaltrials.gov Identifier: NCT02282397.
Literature
1.
go back to reference Santiago JV. Lessons from the diabetes control and complications trial. Diabetes. 1993;42(11):1549–54.CrossRefPubMed Santiago JV. Lessons from the diabetes control and complications trial. Diabetes. 1993;42(11):1549–54.CrossRefPubMed
2.
go back to reference Cariou B, Fontaine P, Eschwege E, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab. 2015;41(2):116–25.CrossRefPubMed Cariou B, Fontaine P, Eschwege E, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab. 2015;41(2):116–25.CrossRefPubMed
3.
go back to reference Cryer PE. Preventing hypoglycaemia: what is the appropriate glucose alert value? Diabetologia. 2009;52(1):35–7.CrossRefPubMed Cryer PE. Preventing hypoglycaemia: what is the appropriate glucose alert value? Diabetologia. 2009;52(1):35–7.CrossRefPubMed
4.
go back to reference Frier BM. Defining hypoglycaemia: what level has clinical relevance? Diabetologia. 2009;52(1):31–4.CrossRefPubMed Frier BM. Defining hypoglycaemia: what level has clinical relevance? Diabetologia. 2009;52(1):31–4.CrossRefPubMed
5.
go back to reference International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40(1):155–7.CrossRef International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40(1):155–7.CrossRef
6.
go back to reference Beck RW, Riddlesworth T, Ruedy K, for the DIAMOND Study Group, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371–8.CrossRefPubMed Beck RW, Riddlesworth T, Ruedy K, for the DIAMOND Study Group, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371–8.CrossRefPubMed
7.
go back to reference Russell SJ, Beck RW. Design considerations for artificial pancreas pivotal studies. Diabetes Care. 2016;39(7):1161–7.CrossRefPubMed Russell SJ, Beck RW. Design considerations for artificial pancreas pivotal studies. Diabetes Care. 2016;39(7):1161–7.CrossRefPubMed
Metadata
Title
Hypoglycemic Event Frequency and the Effect of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections
Authors
Tonya Riddlesworth
David Price
Nathan Cohen
Roy W. Beck
Publication date
01-08-2017
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 4/2017
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-017-0281-4

Other articles of this Issue 4/2017

Diabetes Therapy 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.